Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 3/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.49 |
| ▸ | NPC1 | O15118 | 1/20 | 0.49 |
| ▸ | RAB9A | P51151 | 1/20 | 0.49 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.47 |
| ▸ | CCR3 | P51677 | 1/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17462480 | 0.88 | MEN1 (0.48) | MEN1KMT2ANPC1RAB9ATAAR1 | |
| SCHEMBL29097833 | 0.87 | TAAR1 (0.60) | MEN1KMT2ANPC1RAB9ATAAR1 | |
| SCHEMBL27973340 | 0.86 | KMT2A (0.52) | MEN1KMT2ANPC1RAB9ATAAR1 | |
| SCHEMBL17462497 | 0.85 | MEN1 (0.48) | MEN1KMT2ANPC1RAB9ATAAR1 | |
| SCHEMBL8566606 | 0.80 | MEN1 (0.49) | MEN1KMT2ANPC1RAB9ATAAR1 | |
| SCHEMBL28037513 | 0.78 | KMT2A (0.52) | MEN1KMT2ANPC1RAB9ATAAR1 | |
| SCHEMBL5767226 | 0.76 | MEN1 (0.43) | MEN1KMT2ANPC1RAB9ATAAR1 | |
| SCHEMBL4845542 | 0.76 | ALDH1A1 (0.44) | MEN1KMT2ANPC1RAB9ATAAR1 | |
| SCHEMBL10646677 | 0.76 | MEN1 (0.60) | MEN1KMT2AHTTTDP1 | |
| SCHEMBL2310865 | 0.75 | STING1 (0.54) | MEN1KMT2ANPC1RAB9AHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3172202-B1 | HETEROCYCLIC CARBOXYLIC ACIDS AS ACTIVATORS OF SOLUBLE GUANYLATE CYCLASE | BOEHRINGER INGELHEIM INT (DE) | 2020-01-29 | — | — | EP | disclosed |
| EP-2892891-B1 | ALKOXY PYRAZOLES AS SOLUBLE GUANYLATE CYCLASE ACTIVATORS | BOEHRINGER INGELHEIM INT (DE) | 2019-07-31 | — | — | EP | disclosed |
| US-RE46886-E1 | Alkoxy pyrazoles as soluble guanylate cyclase activators | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2018-06-05 | — | — | US | disclosed |
| US-9353090-B2 | Heterocyclic carboxylic acids as activators of soluble guanylate cyclase | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2016-05-31 | — | — | US | disclosed |
| US-20160024059-A1 | HETEROCYCLIC CARBOXYLIC ACIDS AS ACTIVATORS OF SOLUBLE GUANYLATE CYCLASE | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2016-01-28 | — | — | US | disclosed |
| WO-2016014463-A1 | HETEROCYCLIC CARBOXYLIC ACIDS AS ACTIVATORS OF SOLUBLE GUANYLATE CYCLASE | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2016-01-28 | — | — | WO | disclosed |
| US-8906904-B2 | Alkoxy pyrazoles as soluble guanylate cyclase activators | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-12-09 | — | — | US | disclosed |
| US-20140073629-A1 | ALKOXY PYRAZOLES AS SOLUBLE GUANYLATE CYCLASE ACTIVATORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-03-13 | — | — | US | disclosed |
| WO-2014039434-A1 | ALKOXY PYRAZOLES AS SOLUBLE GUANYLATE CYCLASE ACTIVATORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-03-13 | — | — | WO | disclosed |
| EP-1751163-B1 | BENZAZEPINE COMPOUNDS HAVING AFFINITY FOR DOPAMINE D3 RECEPTOR AND USES THEREOF | GLAXO GROUP LTD (GB) | 2011-08-10 | — | — | EP | disclosed |
| EP-1751163-B1 | BENZAZEPINE COMPOUNDS HAVING AFFINITY FOR DOPAMINE D3 RECEPTOR AND USES THEREOF | GLAXO GROUP LTD (GB) | 2011-08-10 | — | — | EP | disclosed |
| US-7989444-B2 | Compounds having affinity for dopamine D3 receptor and uses thereof | GLAXO GROUP LIMITED (GB) | 2011-08-02 | — | — | US | disclosed |
| US-7989444-B2 | Compounds having affinity for dopamine D3 receptor and uses thereof | GLAXO GROUP LIMITED (GB) | 2011-08-02 | — | — | US | disclosed |
| US-7989444-B2 | Compounds having affinity for dopamine D3 receptor and uses thereof | GLAXO GROUP LIMITED (GB) | 2011-08-02 | — | — | US | disclosed |
| US-20100016287-A1 | COMPOUNDS HAVING AFFINITY FOR DOPAMINE D3 RECEPTOR AND USES THEREOF\ | GLAXO GROUP LIMITED (GB) | 2010-01-21 | — | — | US | disclosed |
| US-20100016287-A1 | COMPOUNDS HAVING AFFINITY FOR DOPAMINE D3 RECEPTOR AND USES THEREOF\ | GLAXO GROUP LIMITED (GB) | 2010-01-21 | — | — | US | disclosed |
| US-20100016287-A1 | COMPOUNDS HAVING AFFINITY FOR DOPAMINE D3 RECEPTOR AND USES THEREOF\ | GLAXO GROUP LIMITED (GB) | 2010-01-21 | — | — | US | disclosed |
| EP-1751163-A2 | COMPOUNDS HAVING AFFINITY FOR DOPAMINE D3 RECEPTOR AND USES THEREOF | GLAXO GROUP LIMITED (GB) | 2007-02-14 | — | — | EP | disclosed |
| WO-2005118549-A2 | COMPOUNDS HAVING AFFINITY FOR DOPAMINE D3 RECEPTOR AND USES THEREOF | GLAXO GROUP LIMITED (GB) | 2005-12-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160024059-A1 | HETEROCYCLIC CARBOXYLIC ACIDS AS ACTIVATORS OF SOLUBLE GUANYLATE CYCLASE | ADCY9, ADCY7, GUCY1B1 | MEN1 1764/4885KMT2A 3415/4885NPC1 2955/4885 |
| US-20100016287-A1 | COMPOUNDS HAVING AFFINITY FOR DOPAMINE D3 RECEPTOR AND USES THEREOF\ | DRD3, DRD2, SLC6A3 | MEN1 4473/4885KMT2A 3603/4885NPC1 2235/4885 |
| US-20140073629-A1 | ALKOXY PYRAZOLES AS SOLUBLE GUANYLATE CYCLASE ACTIVATORS | GUCY1B1, GUCY1A2, GUCY1A1 | MEN1 1788/4885KMT2A 4223/4885NPC1 1683/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.